**Supplementary Figure 1.** Effects of TM-25659 on FGF21 expression and the PKR and PERK pathways. C2 myoblasts were differentiated into C2 myotubes and treated with 10, 20, or 40 µM TM-25659 or vehicle. (A) FGF21 expression in TM-25659-treated skeletal muscle cells with or without PKR siRNA. (B) FGF21 expression in TM-25659-treated skeletal muscle cells with or without PERK siRNA. The data are given as the mean ± standard error. *$P < 0.05$, **$P < 0.01$, †$P < 0.05$. 